Stanley Lipkowitz
Overview
Explore the profile of Stanley Lipkowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshino T, Zhang Z, Sato R, Lipkowitz S, Fujii T
JNCI Cancer Spectr
. 2025 Feb;
PMID: 39992221
Background: Pathological complete response (pCR) has been used as a primary endpoint in neoadjuvant trials in early-stage triple negative breast cancer (TNBC) and the Food and Drug Administration (FDA) accepted...
2.
Ridnour L, Heinz W, Cheng R, Wink A, Kedei N, Pore M, et al.
Cancer Res Commun
. 2024 Oct;
4(10):2766-2782.
PMID: 39356141
This work identifies CD8-NOS2+COX2+ and CD8-NOS2-COX2+ unique cellular neighborhoods that drive the tumor immune spatial architecture of CD8+ T cells predictive of clinical outcome and can be targeted with clinically...
3.
Kundu M, Greer Y, Lobanov A, Ridnour L, Donahue R, Ng Y, et al.
bioRxiv
. 2024 Aug;
PMID: 39091795
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing the non-malignant cells in preclinical models. However, its efficacy in clinical...
4.
Lagerstrom I, Neelon D, Wendzel N, Lipkowitz S, Moncur J, Uiterwaal S, et al.
Arch Pathol Lab Med
. 2024 Jul;
149(3):e72-e77.
PMID: 38952295
Context.—: The Oncotype DX recurrence score (RS) is a widely used test that provides prognostic information on the likelihood of disease recurrence and predictive information on the benefit of chemotherapy...
5.
Ridnour L, Cheng R, Kedei N, Somasundaram V, Bhattacharyya D, Basudhar D, et al.
JCI Insight
. 2024 Jun;
9(12).
PMID: 38912586
Immune therapy is the new frontier of cancer treatment. Therapeutic radiation is a known inducer of immune response and can be limited by immunosuppressive mediators including cyclooxygenase-2 (COX2) that is...
6.
Giudice E, Huang T, Nair J, Zurcher G, McCoy A, Nousome D, et al.
Nat Commun
. 2024 Mar;
15(1):2805.
PMID: 38555285
The multi-cohort phase 2 trial NCT02203513 was designed to evaluate the clinical activity of the CHK1 inhibitor (CHK1i) prexasertib in patients with breast or ovarian cancer. Here we report the...
7.
Kudo K, Greer Y, Yoshida T, Harrington B, Korrapati S, Shibuya Y, et al.
Cancer Gene Ther
. 2024 Feb;
31(5):721-735.
PMID: 38424218
Ovarian cancer follows a characteristic progression pattern, forming multiple tumor masses enriched with cancer stem cells (CSCs) within the abdomen. Most patients develop resistance to standard platinum-based drugs, necessitating better...
8.
Ridnour L, Cheng R, Heinz W, Pore M, Gonzalez A, Femino E, et al.
bioRxiv
. 2024 Jan;
PMID: 38187660
Multiple immunosuppressive mechanisms exist in the tumor microenvironment that drive poor outcomes and decrease treatment efficacy. The co-expression of NOS2 and COX2 is a strong predictor of poor prognosis in...
9.
Ridnour L, Heinz W, Cheng R, Wink A, Kedei N, Pore M, et al.
bioRxiv
. 2024 Jan;
PMID: 38187532
Estrogen receptor-negative (ER-) breast cancer is an aggressive breast cancer subtype with limited therapeutic options. Upregulated expression of both inducible nitric oxide synthase (NOS2) and cyclo-oxygenase (COX2) in breast tumors...
10.
Atkins S, Greer Y, Jenkins S, Gatti-Mays M, Houston N, Lee S, et al.
Oncologist
. 2023 Jun;
28(10):919-e972.
PMID: 37279797
Background: ONC201 is a small molecule that can cause nonapoptotic cell death through loss of mitochondrial function. Results from the phase I/II trials of ONC201 in patients with refractory solid...